title: Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye.
abstract: OBJECTIVE
  Dry eye is a chronic inflammatory ocular surface disease with high prevalence. The current therapies for dry eye remain to be unspecific and notcomprehensive. This study aims to explore safety and efficacy of a novel treatment - subconjunctival injection of bevacizumab - in dry eye patients.
  
  
  METHODS
  Sixty-four eyes of 32 dry eye patients received subconjunctival injection of 100 μL 25 mg/mL bevacizumab. Dry eye symptoms, signs (corrected visual acuity, intraocular pressure, conjunctival vascularity, corneal staining, tear break-up time, Marx line score, and blood pressure), and conjunctival impression cytology were evaluated 3 days before and 1 week, 1 month, and 3 months after injection.
  
  
  RESULTS
  Significant improvements were observed in dry eye symptoms, tear break-up time, and conjunctival vascularization area at all the visits after injection compared to the baseline (P<0.05). The density of the goblet cell increased significantly at 1 month and 3 months after injection (P<0.05). There was no visual and systemic threat observed in any patient.
  
  
  CONCLUSIONS
  Subconjunctival injection of 100 μL 25 mg/mL bevacizumab is a safe and efficient treatment for ocular surface inflammation of dry eye disease.
authors.affiliation: Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
authors.forename: Xiaodan
authors.initials: X
authors.lastname: Jiang
authors.affiliation: Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
authors.forename: Huibin
authors.initials: H
authors.lastname: Lv
authors.affiliation: Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
authors.forename: Weiqiang
authors.initials: W
authors.lastname: Qiu
authors.affiliation: Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
authors.forename: Ziyuan
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
authors.forename: Xuemin
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Ophthalmology, Peking University Third Hospital, Beijing, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D003228:Conjunctiva / Q000098:blood supply / Q000473:pathology; D003315:Cornea / Q000473:pathology; D015352:Dry Eye Syndromes / Q000188:drug therapy*; D005260:Female; D020397:Goblet Cells / Q000187:drug effects; D006801:Humans; D007267:Injections; D008297:Male; D008537:Meibomian Glands / Q000473:pathology; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D013666:Tears / Q000187:drug effects; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: anti-VEGF; bevacizumab; dry eye; ocular surface inflammation; subconjunctival